Exercise period for BrainCool’s warrants, TO2 2018-2021, 18 September – 2 October 2019
As part of our agreement with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of September 18 to October 2, 2019, holders of TO2 Warrants can exercise the Warrants and subscribe for new shares. One (1) TO2 warrant can be exchanged for one (1) share, at a price of 7 SEK.
The current market price is below the exercise price. Unless the market price exceeds the exercise price, it is not beneficial to subscribe in the current exercise period. Therefore, the application form has not been sent to the shareholders. If shareholders do want to exercise warrants, we advise them to contact the company’s share agent, Eminova Fondkommission, by phone at 08-684 211 00 or by email at email@example.com.
-Subscription of shares based on the warrants may take place during the following periods: ·
- 18 September 2019 through 2 October 2019
- 19 March 2020 through 2 April 2020
- 18 September 2020 through 2 October 2020
- 17 March 2021 through 31 March 2021
- 17 September 2021 through 1 October 2021
-Holders of warrants series TO2 2018/2021 for a total value of SEK 500,000 or more may always exercise the warrants for subscription of shares, i.e. from the date of listing to and including October 1, 2021.
-Warrants of series TO2 have ISIN code SE0011762418.
For terms and conditions of the warrants, please visit BrainCool’s website:
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.